Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
$9.14
+2.4%
$8.25
$2.99
$10.28
$1.39B1.751.57 million shs1.38 million shs
Exscientia plc stock logo
EXAI
Exscientia
$4.84
$4.97
$3.80
$6.49
$632.93M0.83654,123 shsN/A
Inhibrx, Inc. stock logo
INBX
Inhibrx
$13.13
+2.1%
$12.46
$10.80
$34.58
$190.07MN/A156,523 shs100,655 shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$9.07
-6.6%
$7.86
$5.04
$15.39
$487.05M1.11886,153 shs1.68 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
+2.35%-2.35%+15.70%+9.33%+165.70%
Exscientia plc stock logo
EXAI
Exscientia
0.00%0.00%0.00%0.00%+3.20%
Inhibrx, Inc. stock logo
INBX
Inhibrx
+2.10%+0.46%+7.10%+4.21%-61.54%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-6.59%-9.30%-0.87%+35.98%-39.21%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
3.5821 of 5 stars
1.44.00.04.24.32.50.6
Exscientia plc stock logo
EXAI
Exscientia
0.1298 of 5 stars
1.00.00.00.00.01.70.6
Inhibrx, Inc. stock logo
INBX
Inhibrx
2.2423 of 5 stars
0.02.00.04.63.02.51.3
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
4.2352 of 5 stars
3.42.00.04.62.73.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
2.83
Moderate Buy$9.837.59% Upside
Exscientia plc stock logo
EXAI
Exscientia
2.00
Hold$5.003.31% Upside
Inhibrx, Inc. stock logo
INBX
Inhibrx
2.00
HoldN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2.83
Moderate Buy$31.63248.68% Upside

Current Analyst Ratings Breakdown

Latest EXAI, RGNX, INBX, and ADPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Inhibrx, Inc. stock logo
INBX
Inhibrx
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/6/2025
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.00
5/5/2025
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.00
5/2/2025
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
4/17/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00
3/21/2025
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$8.00 ➝ $9.00
3/20/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
3/18/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$24.00
3/17/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$36.00 ➝ $34.00
3/14/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$22.00 ➝ $24.00
3/14/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
$189.53M7.33N/AN/A$1.37 per share6.67
Exscientia plc stock logo
EXAI
Exscientia
$25.60M24.72N/AN/A$2.54 per share1.91
Inhibrx, Inc. stock logo
INBX
Inhibrx
$200K950.35N/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$156.72M2.90N/AN/A$7.09 per share1.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
-$159.49M-$0.96N/AN/AN/A-89.12%-64.65%-26.45%8/7/2025 (Estimated)
Exscientia plc stock logo
EXAI
Exscientia
-$181.56M-$1.51N/AN/AN/A-882.09%-49.10%-33.13%N/A
Inhibrx, Inc. stock logo
INBX
Inhibrx
-$154.96M$116.750.11N/AN/AN/A-113.74%-80.56%6/16/2025 (Estimated)
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$263.49M-$3.11N/AN/AN/A-283.19%-70.65%-41.68%8/7/2025 (Estimated)

Latest EXAI, RGNX, INBX, and ADPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q4 2024
Inhibrx, Inc. stock logo
INBX
Inhibrx
-$2.55-$2.80-$0.25-$2.80N/AN/A
5/12/2025Q1 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$0.41$0.12-$0.29$0.12$105.35 million$89.01 million
5/1/2025Q1 2025
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 million
3/17/2025Q4 2024
Inhibrx, Inc. stock logo
INBX
Inhibrx
-$2.88-$3.09-$0.21-$3.09N/A$0.10 million
3/13/2025Q4 2024
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$1.27-$1.01+$0.26-$1.01$23.70 million$21.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Exscientia plc stock logo
EXAI
Exscientia
N/AN/AN/AN/AN/A
Inhibrx, Inc. stock logo
INBX
Inhibrx
N/AN/AN/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
N/A
2.89
2.81
Exscientia plc stock logo
EXAI
Exscientia
0.06
4.54
4.54
Inhibrx, Inc. stock logo
INBX
Inhibrx
N/A
4.70
4.70
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/A
3.05
3.05

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
99.17%
Exscientia plc stock logo
EXAI
Exscientia
41.58%
Inhibrx, Inc. stock logo
INBX
Inhibrx
82.46%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
88.08%

Insider Ownership

CompanyInsider Ownership
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
6.40%
Exscientia plc stock logo
EXAI
Exscientia
16.40%
Inhibrx, Inc. stock logo
INBX
Inhibrx
17.09%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
12.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
790151.92 million138.43 millionOptionable
Exscientia plc stock logo
EXAI
Exscientia
280130.77 million109.32 millionOptionable
Inhibrx, Inc. stock logo
INBX
Inhibrx
16614.48 million11.26 millionOptionable
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
37050.16 million43.04 millionOptionable

Recent News About These Companies

FY2025 EPS Estimate for REGENXBIO Decreased by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$9.14 +0.21 (+2.35%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$9.16 +0.02 (+0.22%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Exscientia stock logo

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Inhibrx stock logo

Inhibrx NASDAQ:INBX

$13.13 +0.27 (+2.10%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$13.15 +0.02 (+0.15%)
As of 05/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

REGENXBIO stock logo

REGENXBIO NASDAQ:RGNX

$9.07 -0.64 (-6.59%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$9.15 +0.08 (+0.88%)
As of 05/27/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.